Wave Life Sciences Ltd (WVE)

Currency in USD
7.635
+0.245(+3.32%)
Real-time Data·
WVE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.3007.740
52 wk Range
5.02021.730
Key Statistics
Prev. Close
7.39
Open
7.48
Day's Range
7.3-7.74
52 wk Range
5.02-21.73
Volume
2.37M
Average Vol. (3m)
4.14M
1-Year Change
21.5764%
Book Value / Share
2.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WVE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.933
Upside
+226.57%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Wave Life Sciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Wave Life Sciences Ltd SWOT Analysis


Financial Health
Discover Wave's financial landscape, balancing a healthy current ratio against rapid cash burn, as it navigates critical development stages in the biotech secto
Market Positioning
Learn how Wave aims to differentiate itself in competitive markets through less frequent dosing and novel mechanisms, with analyst price targets ranging from $9 to $36
Clinical Milestones
Delve into Wave's pipeline progress, with key data readouts expected in 2025 for AATD and obesity programs, potentially validating its RNA editing platform
RNA Editing Pionee
Explore Wave Life Sciences' innovative approach to genetic medicine, leveraging RNA editing technology for potential breakthroughs in AATD, obesity, and other disorders
Read full SWOT analysis

Wave Life Sciences Ltd Earnings Call Summary for Q4/2025

  • Q4 2025 revenue fell 79.5% YoY to $17.2M following Takeda collaboration termination in October 2024; EPS loss of $0.30 missed forecast.
  • Full-year 2025 revenue declined to $42.7M from $108.3M in 2024; company maintains strong cash position of $602.1M with runway into Q3 2028.
  • Stock rose 0.28% in pre-market trading despite EPS miss; shares up 46% over six months but down 14% year-to-date amid high volatility.
  • Company focuses on advancing RNA editing pipeline programs and anticipates additional milestone payments from GSK collaboration to strengthen finances.
  • Management emphasizes strategic partnerships while navigating challenges from lost Takeda revenue and increased R&D expenses in competitive biotech sector.
Last Updated: 02/26/2026, 10:08 AM
Read Full Transcript

Compare WVE to Peers and Sector

Metrics to compare
WVE
Peers
Sector
Relationship
P/E Ratio
−6.9x−7.2x−0.5x
PEG Ratio
0.09−0.140.00
Price / Book
2.7x2.0x2.6x
Price / LTM Sales
33.0x10.8x3.2x
Upside (Analyst Target)
183.6%36.6%47.6%
Fair Value Upside
Unlock−5.7%6.1%Unlock

Analyst Ratings

16 Buy
0 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.933
(+226.57% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy18.00+137.47%30.00MaintainApr 14, 2026
Wedbush
Buy15.00+97.89%35.00MaintainMar 27, 2026
Wells Fargo
Buy13.00+71.50%27.00MaintainMar 27, 2026
Clear Street
Buy39.00+414.51%50.00MaintainMar 26, 2026
Clear Street
Buy39.00+414.51%50.00MaintainMar 26, 2026

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.30 / -0.27
Revenue / Forecast
17.24M / 17.16M
EPS Revisions
Last 90 days

WVE Income Statement

People Also Watch

9.730
ONDS
+3.51%
16.36
OLMA
+0.37%
7.59
IBRX
-0.20%
815.98
LITE
-4.32%

FAQ

What Is the Wave Life Sciences Ltd (WVE) Stock Price Today?

The Wave Life Sciences Ltd stock price today is 7.635 USD.

What Stock Exchange Does Wave Life Sciences Ltd Trade On?

Wave Life Sciences Ltd is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Wave Life Sciences Ltd?

The stock symbol for Wave Life Sciences Ltd is "WVE."

What Is the Wave Life Sciences Ltd Market Cap?

As of today, Wave Life Sciences Ltd market cap is 1.420B USD.

What Is Wave Life Sciences Ltd's Earnings Per Share (TTM)?

The Wave Life Sciences Ltd EPS (TTM) is -1.212.

When Is the Next Wave Life Sciences Ltd Earnings Date?

Wave Life Sciences Ltd will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is WVE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Wave Life Sciences Ltd Stock Split?

Wave Life Sciences Ltd has split 0 times.

How Many Employees Does Wave Life Sciences Ltd Have?

Wave Life Sciences Ltd has 317 employees.

What is the current trading status of Wave Life Sciences Ltd (WVE)?

As of Apr 15, 2026, Wave Life Sciences Ltd (WVE) is trading at a price of 7.635 USD, with a previous close of 7.390 USD. The stock has fluctuated within a day range of 7.300 USD to 7.740 USD, while its 52-week range spans from 5.020 USD to 21.730 USD.

What Is Wave Life Sciences Ltd (WVE) Price Target According to Analysts?

The average 12-month price target for Wave Life Sciences Ltd is 24.933 USD, with a high estimate of 52 USD and a low estimate of 11 USD. 16 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +226.57% Upside potential.

What Is the WVE Premarket Price?

WVE's last pre-market stock price is 7.470 USD. The pre-market share volume is 5,670.000, and the stock has decreased by 0.080, or 1.080%.

What Is the WVE After Hours Price?

WVE's last after hours stock price is 7.400 USD, the stock has decreased by 0.010, or 0.140%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.